Paul Hudson, CEO of Sanofi.
The French laboratory Sanofi has announced that it will stop the development of its messenger RNA vaccine against Covid-19, although work will continue to develop its other vaccine against the virus, currently in clinical trials.
Although positive intermediary results for phases 1 and 2 of the trials of its messenger RNA technology vaccine, Sanofi believes that it would arrive too late to market, when 12,000 million doses of anticovid vaccines in total will have been produced before the end of the year.
The results of the phase 3 of your other vaccine, based on a recombinant protein and developed with Britain’s GSK, are expected before the end of 2021.
“The need is not to create new Covid-19 RNA vaccines, but to provide France and Europe with a messenger RNA vaccine arsenal for a next pandemic, for new pathologies “assures the environment AFP Thomas Triomphe, Vice President of Sanofi’s Vaccine Branch.
Consequently, Sanofi will not develop phase 3 for this vaccine “as there is no public health need to have another messenger RNA vaccine, “he added.
Although it may contain statements, data or notes from health institutions or professionals, the information contained in Medical Writing is edited and prepared by journalists. We recommend the reader that any health-related question be consulted with a healthcare professional.